EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants

Takehiko Sambe, Takuya Miwa, Koichiro Yoneyama, Takaaki Ishida, Taigi Yamazaki, Midori Shima

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.06.013 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Takehiko Sambe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Department of Clinical Pharmacology, Gra…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Blood Coagulation, Factor VIII. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: NXT007 is a bispecific antibody that mimics the cofactor function of activated factor (F)VIII and was engineered by modifying emicizumab. Nonclinical investigations suggested its potential to provide nonhemophilic concentrations of coagulation activity to people with hemophilia A. A first-in-human, single-ascending dose study of NXT007 was conducted in healthy Japanese male adults (part A of the NXTAGE study). OBJECTIVES: To evaluate safety, immunogenicity, pharmacokinetics, and pharmacodynamics of NXT007. METHODS: Forty participants were enrolled across 5 cohorts and randomized to receive a single subcutaneous injection of NXT007 (n = 6 per cohort; 0.0018, 0.0054, 0.018, 0.054, or 0.18 mg/kg) or placebo (n = 2 per cohort). RESULTS: There were no dose-dependent increases in the incidence of adverse events, and no thrombotic events or injection-site reactions were reported. One serious adverse event of erythema was reported in a participant who received NXT007 0.0054 mg/kg, and its causality to NXT007 could not be ruled out. Nine participants developed anti-NXT007 antibodies; all were considered to be associated with faster clearance of NXT007 without impacting safety. NXT007 exposure increased dose-dependently but less than dose proportionally. The elimination half-life of NXT007 was approximately 10 weeks in antidrug antibody-negative participants. With ex vivo neutralization of endogenous FVIII in plasma samples, activated partial thromboplastin time was shortened, and thrombin generation was promoted in a dose-dependent manner. CONCLUSION: A single subcutaneous injection of NXT007 was well tolerated without occurrence of thrombotic events. The long half-life, pharmacological effect, and safety profile supported study progression to the subsequent multiple ascending dose parts of the NXTAGE study in people with hemophilia A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificBlood CoagulationFactor VIIIHumansMaleAdultHealthy VolunteersInjections, SubcutaneousYoung AdultMiddle AgedHemophilia AJapanDose-Response Relationship, DrugHalf-LifeDouble-Blind MethodAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

bispecific antibodieshemophilia Apharmacokineticsphase I clinical trialsafety

Substanzen

Antibodies, BispecificFactor VIIIemicizumabF8 protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Research Center for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; Department of Clinical Pharmacology, Graduate School of Medicine, Showa Medical University, Tokyo, Japan.
  • Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.
  • Clinical Research Center for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
  • Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan. Electronic address: mshima@naramed-u.ac.jp.

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Sambe, T., Miwa, T., Yoneyama, K., Ishida, T., Yamazaki, T., & Shima, M. (2025). A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.06.013

Vancouver

Sambe T, Miwa T, Yoneyama K, Ishida T, Yamazaki T, Shima M. A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.06.013

BibTeX
@article{Sambe2025,
  author = {Sambe, Takehiko and Miwa, Takuya and Yoneyama, Koichiro and Ishida, Takaaki and Yamazaki, Taigi and Shima, Midori},
  title = {A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.06.013}
}
Kostenlos starten →